Medivir Ab

Medivir Aktiebolag

Mark Albertella

Björn Klasson

John Öhd

Anders Eneroth

Fredrik Öberg

Bjorn Klasson

Fredrik Oberg

Pedro Pinho

John Ohd

Compounds of the formula I wherein X is a bond or —CH, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and/or over 60 years of age.

Base-modified cytidine nucleotides for leukemia therapy

Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C-Cstraight or branched chain alkyl, X is H, halo, C-Ccycloalkyl or C-Calkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis.

Sorafenib or regorafenib troxacitabine phosphoramidate prodrug combination therapy for liver cancer

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine with the formula: where Y is C-Cstraight or branched chain alkyl, X is H, halo, C-Ccycloalkyl or C-Calkyl and Z is H or fluoro, or a pharmaceutically acceptable salt thereof, shows surprising utility in the treatment of liver cancer or liver metastasis. 

Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Growing community of inventors

Huddinge, Sweden

Mark Albertella